Wegovy for metabolic dysfunction-associated steatohepatitis (mash)
How Wegovy (semaglutide) is used in metabolic dysfunction-associated steatohepatitis (mash), what the clinical evidence shows, and how it compares to other treatment options.
Metabolic dysfunction-associated steatohepatitis (MASH): what it is
MASH (formerly NASH) is the inflammatory form of metabolic dysfunction-associated fatty liver disease (MASLD). Characterized by hepatic steatosis plus inflammation and hepatocyte injury, with risk of progression to cirrhosis. Tightly linked to obesity, T2D, and metabolic syndrome. Renamed from NASH in 2023 (American Association for the Study of Liver Diseases consensus).
How Wegovy fits into metabolic dysfunction-associated steatohepatitis (mash) treatment
Weight loss is the most evidence-supported intervention: 7-10% body weight loss reverses MASH in most patients. GLP-1 receptor agonists (semaglutide, tirzepatide) show histologic improvement in trials and are first-line where comorbid obesity or T2D exists. Resmetirom (Rezdiffra, FDA-approved 2024) is the first MASH-specific drug. Bariatric surgery for severe disease with concurrent severe obesity.
Wegovy works by: Semaglutide mimics GLP-1, a gut hormone released after meals. It slows stomach emptying (you feel full longer), suppresses appetite (reduced food-noise signaling in the brain), and improves insulin sensitivity. The combined effect is sustained appetite reduction and meaningful weight loss for most patients.
Who qualifies for Wegovy for metabolic dysfunction-associated steatohepatitis (mash)
FDA-approved for adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity (high blood pressure, prediabetes, sleep apnea, dyslipidemia). Also approved for adolescents 12+ at the 95th percentile BMI. Contraindicated in personal/family history of medullary thyroid cancer or MEN2.
Off-label note: Wegovy is not FDA-approved for metabolic dysfunction-associated steatohepatitis (mash). Off-label prescribing is legal and clinically appropriate when supported by evidence and shared clinical decision-making. Insurance coverage for off-label use is often more difficult than for labeled indications — expect prior-authorization challenges and stronger documentation requirements.
Clinical evidence
14.9% mean body-weight reduction at 68 weeks
Trial: STEP 1 (NCT03548935) · vs 2.4% with placebo + lifestyle · N = 1,961
How Wegovy compares to other metabolic dysfunction-associated steatohepatitis (mash) treatments
Frequently asked about metabolic dysfunction-associated steatohepatitis (mash)
- What's the difference between MASLD and MASH?
- MASLD (metabolic dysfunction-associated steatotic liver disease) is the umbrella term for steatosis with metabolic risk factors — replaces the older NAFLD nomenclature. MASH (metabolic dysfunction-associated steatohepatitis) is the progressive form with active inflammation and hepatocyte ballooning, ~5% of MASLD patients. MASH carries fibrosis-progression risk; pure steatosis without MASH usually does not.
- Will losing weight reverse my fatty liver?
- Yes — 7-10% sustained body-weight loss reverses MASH in most patients with concurrent improvement in fibrosis. GLP-1 receptor agonists (semaglutide, tirzepatide) produce this magnitude of weight loss reliably and have direct hepatic anti-inflammatory effects beyond the weight component in trials.
- Is Rezdiffra (resmetirom) the same as a GLP-1?
- No. Rezdiffra (resmetirom) is a thyroid hormone receptor β agonist — a different mechanism. It's FDA-approved (2024) specifically for non-cirrhotic MASH with significant fibrosis. GLP-1s are not MASH-labeled but are increasingly used for the overlap of obesity, T2D, and MASH where weight loss is itself the treatment.
- Should I avoid alcohol if I have MASH?
- Yes. MASH and alcohol-related liver disease are synergistic — even moderate alcohol amplifies MASH progression. Most hepatology guidance recommends abstinence or very minimal use (≤1 drink/week) in established MASH, particularly with any fibrosis.